综述:结直肠癌化疗
发布于 2004-01-31 · 浏览 2741 · IP 广西广西
这个帖子发布于 21 年零 108 天前，其中的信息可能已发生改变或有所发展。
文题：Review article: colorectal cancer chemotherapy
作者：Gill S, Thomas RR, Goldberg RM.
杂志全名： Alimentary pharmacology & therapeutics.
年份，卷（期）: 起止页码：2003 Oct 1;18(7):683-92.
英文摘要Colorectal cancer is a leading cause of cancer death world-wide. There have been important advances in the chemotherapeutic management of colorectal cancer as a result of a deliberate collaborative process of well-designed clinical trials. From the earlier standard of 5-fluorouracil-based therapy alone, the recent availability of newer agents, including capecitabine, irinotecan and oxaliplatin, has significantly expanded the options available for the management of patients with advanced colorectal cancer, with consequent improvements in survival. For patients with resected, high-risk, localized disease, adjuvant systemic chemotherapy improves survival. The identification of new chemotherapy regimens, the use of predictive testing and the integration of novel targeted therapies with cytotoxic chemotherapies are areas of active clinical investigation. A review of the chemotherapeutic management of colorectal cancer is presented.
中文译文：结直肠癌是全世界的癌症死亡的一个重要原因.由于有设计优良的临床试验的精心的协作过程,再结直肠癌的化疗方面取得重要的进步.从单独以5-FU为基础的早期治疗标准开始,最近有许多新的药物:卡培他宾,依立替康,奥沙利铂的使用,使大大地拓展了进展期结直肠癌病人治疗的选择,而且生存期延长.对于那些可切除的,高危险性的局部病变,辅助全身化疗明显延长了生存期.新的化疗方案的确定,预测性试用的运用,细胞毒性药物联合新的靶向治疗都是活跃的临床观察的领域.结直肠癌化学治疗的综述如下.
版权声明：本译文文字内容版权归丁香园网站（ http://www.dxy.cn ）所有，未经本网站书面许可，请勿转载或摘编
作者：Gill S, Thomas RR, Goldberg RM.
杂志全名： Alimentary pharmacology & therapeutics.
年份，卷（期）: 起止页码：2003 Oct 1;18(7):683-92.
英文摘要Colorectal cancer is a leading cause of cancer death world-wide. There have been important advances in the chemotherapeutic management of colorectal cancer as a result of a deliberate collaborative process of well-designed clinical trials. From the earlier standard of 5-fluorouracil-based therapy alone, the recent availability of newer agents, including capecitabine, irinotecan and oxaliplatin, has significantly expanded the options available for the management of patients with advanced colorectal cancer, with consequent improvements in survival. For patients with resected, high-risk, localized disease, adjuvant systemic chemotherapy improves survival. The identification of new chemotherapy regimens, the use of predictive testing and the integration of novel targeted therapies with cytotoxic chemotherapies are areas of active clinical investigation. A review of the chemotherapeutic management of colorectal cancer is presented.
中文译文：结直肠癌是全世界的癌症死亡的一个重要原因.由于有设计优良的临床试验的精心的协作过程,再结直肠癌的化疗方面取得重要的进步.从单独以5-FU为基础的早期治疗标准开始,最近有许多新的药物:卡培他宾,依立替康,奥沙利铂的使用,使大大地拓展了进展期结直肠癌病人治疗的选择,而且生存期延长.对于那些可切除的,高危险性的局部病变,辅助全身化疗明显延长了生存期.新的化疗方案的确定,预测性试用的运用,细胞毒性药物联合新的靶向治疗都是活跃的临床观察的领域.结直肠癌化学治疗的综述如下.
版权声明：本译文文字内容版权归丁香园网站（ http://www.dxy.cn ）所有，未经本网站书面许可，请勿转载或摘编
最后编辑于 2022-10-09 · 浏览 2741
2 7 2
